The DFU information was released with the CR presentation back...

The DFU information was released with the CR presentation back in April (slides 17-19): https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02652273-7NSCRSUGSJJKGVONAOHJ1S31OE/pdf?access_token=0007YUZeQM9jdt0x5ryaOwTUcoAr

What is notable is the inclusion of more preclinical data demonstrating Cymerus MSCs reduction of heterogeneity compared to tissue-derived MSCs. Heterogeneity is a major hurdle to the commercialisation of MSC therapies. As the FDA noted in the ODAC briefing document for Rem-L, in the absence of outstanding results from a well-controlled clinical trial, the therapy at the very least needs to have a mechanism of action (MOA) consistent with what is observed in laboratory testing. If the underlying treatment is not consistent on a batch-to-batch basis, that makes it difficult to achieve. Fortunately, a single blood donation is the foundation for 21 million clinical doses of Cymerus MSCs, greatly improving the probability that the clinical MOA will closely match what is expected.